Modality
ADC
MOA
IL-17i
Target
CFTR
Pathway
DDR
CKDFabry
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
Feb 2020
→ Jul 2031
Phase 2Current
NCT05383731
1,205 pts·CKD
2024-08→2028-04·Terminated
NCT04655919
865 pts·Fabry
2020-02→2031-07·Recruiting
2,070 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-042.0y awayPh2 Data· CKD
2031-07-025.3y awayPh2 Data· Fabry
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2028-04-04 · 2.0y away
CKD
Ph2 Data
2031-07-02 · 5.3y away
Fabry
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05383731 | Phase 2 | CKD | Terminated | 1205 | PFS |
| NCT04655919 | Phase 2 | Fabry | Recruiting | 865 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |